2 results
Approved WMOCompleted
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
Approved WMORecruiting
Primary objective:To assess the long term safety and tolerability of GIVINOSTAT in patients with DMD following core protocols program and with naïve GIVINOSTAT DMD subjects , i.e. subjects screened in study DSC/14/2357/48 who met:- all the inclusion…